Shukra Medtech Ltd Growth Catalysts - SOIC x StockScans Report
as of Jul 2026
- Afghanistan medicines contract - A ₹24.06 cr Letter of Award from HSCC (India) for supply of medicines and diagnostic kits to Afghanistan is in hand, with delivery at the consignee site. At roughly 40% of the most recent full-year revenue of ₹56.73 cr, this single order materially lifts near-term revenue.
- Rajasthan formulations contract - A Letter of Acceptance from RMSCL for supply of essential pharmaceutical formulations to Rajasthan government institutions carries a total value of ₹11.59 cr, with supplies scheduled through December 2026. The contract adds another \~20% to the revenue base and runs across multiple quarters, providing visible top-line support.
- 28-manufacturer surgical and medical device alliances - Shukra signed distributorship arrangements with 28 manufacturers including Trivitron, B. Braun, Convatec, and Molnlycke, covering products from hematology analyzers to advanced wound dressings and orthopedic implants. The breadth of the portfolio and the number of partners create multiple new revenue streams from the medical devices and surgical instruments market.
- DGAFMS medical devices distribution - Integra Medical Devices authorized Shukra as distributor for all DGAFMS purchases across India through December 2026, covering defence hospitals, commands, and related organizations. Management expects enhanced revenue visibility and improved margins from premium medical device offerings supplied to defence institutions.
- Promoter warrant funding - Promoter entities were allotted 24.08 lakh convertible warrants in January 2026, with ₹3.95 cr paid upfront and the balance ₹11.84 cr payable within 18 months, earmarked for working capital, bank guarantee margins, and subsidiary capex. The infusion funds the working-capital needs of the growing government contract book and the new subsidiaries without adding debt to a balance sheet that carries only ₹5 cr of borrowings.
- Surgical robotics entry - Borns Medical Robotics MOU - A non-binding MOU with Borns Medical Robotics Inc., USA, signed January 2026, aims to commercialize AI-enabled soft-tissue surgical robotic systems across India and five South Asian markets through the 85%-owned subsidiary Shukra Robotics. The collaboration opens a path into high-value, technology-driven healthcare segments, though it remains at an exploratory stage pending definitive agreements.
- APITCO government healthcare project management - A Service Agreement executed in July 2025 with APITCO Limited, a Government of India PSU, positions Shukra as a Business Associate and Healthcare Project Management Consultant for government healthcare assignments. The partnership provides an institutional channel into government healthcare projects beyond product supply.
- Injectable plant - A new injectable manufacturing plant has been set up, backed by the company's R&D base. The facility adds a higher-value dosage form to the manufacturing capability, broadening the product range available for both domestic tenders and export markets.